Status:
COMPLETED
ASA 81 mg vs 162 mg During Frozen Embryo Transfer (FET)
Lead Sponsor:
Clinique Ovo
Conditions:
Fertility Disorders
Eligibility:
FEMALE
Up to 40 years
Brief Summary
The use of low dose aspirin is recommended for high risk patients to reduce the risk of pre-eclampsia, placental abruption and antepartum hemorrhage. Recent studies have shown that in a specific popul...
Eligibility Criteria
Inclusion
- Women taking aspirin 81 mg or 162 mg prior to an autologous embryo transfer
- Age \< 40 years old
- Embryo transfer cycle done at clinique ovo
Exclusion
- Egg or embryo recipient
- History of recurrent miscarriages, defined as ≥ 3 consecutive losses
- Patients that needed Viagra, PRP or other modalities to improve their endometrial thickness
- Uterine factor infertility
- Abnormal hormonal profiles
- Stimulated embryo transfer cycles
- History of recurrent implantation failure defined as failed ≥ 2 euploid embryos transfer or ≥ 3 blastocysts
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 18 2024
Estimated Enrollment :
1207 Patients enrolled
Trial Details
Trial ID
NCT06128395
Start Date
November 1 2023
End Date
September 18 2024
Last Update
December 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Clinique Ovo
Montreal, Quebec, Canada, H4P 2S4